Montelukast För Barn Från 2 Till 5 År Accord

Montelukast, the active ingredient in Montelukast För Barn Från 2 Till 5 År Accord, is a leukotriene receptor antagonist presented as an oral formulation for use in children aged two to five years. It is indicated for the prophylaxis and chronic treatment of asthma, prevention of exercise‑induced bronchoconstriction, and symptomatic relief of allergic rhinitis.

GNH USA supplies Montelukast För Barn Från 2 Till 5 År Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways that contribute to airway inflammation and allergic symptoms. It is used for several paediatric respiratory conditions: - Asthma: provides prophylaxis and chronic control of symptoms in children 2‑5 years old. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing triggered by physical activity. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate discomfort. - Abdominal pain: occasional stomach upset. - Cough: transient irritation of the throat. - Sore throat: mild irritation. - Nausea: occasional feeling of queasiness. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: agitation, anxiety, or depressive symptoms. - Suicidal thoughts: rare but reported ideation. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Montelukast for young children, several safety considerations are recommended. - Age limitation: use only in children aged 2‑5 years as indicated. - Hepatic impairment: exercise caution and monitor liver function. - Concomitant asthma therapy: ensure compatibility with inhaled corticosteroids or bronchodilators. - Psychiatric monitoring: observe for mood swings or behavioral changes. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or therapeutic response.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing montelukast levels. - Rifampin: strong enzyme inducer that may lower efficacy. - Ketoconazole: potent CYP3A4 inhibitor, potentially increasing exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant effect; monitor INR. - Theophylline: possible additive bronchodilator effect. - Beta‑agonists: monitor for enhanced bronchodilation and side‑effects.